SCHEMBL1269476

SCHEMBL1269476

CC(=O)CC(C(=O)O)N1C(=O)CCC1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
PKM P14618 1/20 0.53
KMT2A Q03164 2/20 0.42
ATM Q13315 1/20 0.42
MME P08473 1/20 0.37
SLC1A2 P43004 2/20 0.36
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
LMNA P02545 1/20 0.32
MEN1 O00255 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA3 P07451 1/20 0.32
CA4 P22748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8629351 0.85 ALDH1A1 (0.42) ALDH1A1PKMKMT2AATMSLC1A2
SCHEMBL2332165 0.84 ALDH1A1 (0.56) ALDH1A1PKMKMT2AATMMME
SCHEMBL604671 0.84 ALDH1A1 (0.56) ALDH1A1PKMKMT2AATMMME
SCHEMBL2913712 0.83 ALDH1A1 (0.40) ALDH1A1PKMKMT2AATMSLC1A2
Propionic Acid SCHEMBL7866660 0.81 ALDH1A1 (0.50) ALDH1A1PKMKMT2AATMMME
Ethylene SCHEMBL29141463 0.81 ALDH1A1 (0.53) ALDH1A1PKMKMT2AATMMME
SCHEMBL30302184 0.81 ALDH1A1 (0.53) ALDH1A1PKMKMT2AATMMME
SCHEMBL2513933 0.81 ALDH1A1 (0.53) ALDH1A1PKMKMT2AATMMME
SCHEMBL2516387 0.81 ALDH1A1 (0.53) ALDH1A1PKMKMT2AATMMME
Ethylene SCHEMBL8387032 0.81 ALDH1A1 (0.53) ALDH1A1PKMKMT2AATMMME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101052617-B Process for the preparation of alkyl 5-(dicarboximido)levulinate and alkyl 4-oxo-pentenoate BIOSYNTH AB 2010-11-03 CN claimed
CN-101052617-A Process for the preparation of alkyl 5-(dicarboximido)levulinate and alkyl 4-oxo-pentenoate BIOSYNTH AB (SE) 2007-10-10 CN claimed
US-20220289809-A1 USE OF RELAXIN TO TREAT ATRIAL FIBRILLATION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-09-15 US disclosed
US-10759846-B2 Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2020-09-01 US disclosed
US-20200087371-A1 USE OF RELAXIN TO TREAT ATRIAL FIBRILLATION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-03-19 US disclosed
US-20190256579-A1 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2019-08-22 US disclosed
US-10301377-B2 Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2019-05-28 US disclosed
US-20180244756-A1 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2018-08-30 US disclosed
EP-3261665-A1 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE The United States of America, as represented by The Secretary, Department of Health and Human Services (US) 2018-01-03 EP disclosed
US-20170342120-A1 USE OF RELAXIN TO TREAT ATRIAL FIBRILLATION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2017-11-30 US disclosed
WO-2016138160-A1 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2016-09-01 WO disclosed
EP-1812474-A2 MULTI-DOMAIN AMPHIPATHIC HELICAL PEPTIDES AND METHODS OF THEIR USE The United States of America as represented by The Secretary, Department of Health and Human Services National Institutes of Health (US) 2007-08-01 EP disclosed
EP-1765394-A1 METHODS FOR PREPARING IMMUNOGENIC CONJUGATES THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2007-03-28 EP disclosed
WO-2007008904-A2 TARGETING POLY-GAMMA-GLUTAMIC ACID TO TREAT STAPHYLOCOCCUS EPIDERMIDIS AND RELATED INFECTIONS THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2007-01-18 WO disclosed
US-20060134143-A1 Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE 2006-06-22 US disclosed
WO-2006044596-A2 MULTI-DOMAIN AMPHIPATHIC HELICAL PEPTIDES AND METHODS OF THEIR USE THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2006-04-27 WO disclosed
EP-1633778-A1 POLY-GAMMA-GLUTAMIC ACID CONJUGATES FOR ELICITING IMMUNE RESPONSES DIRECTED AGAINST BACILLI THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2006-03-15 EP disclosed
WO-2005117965-A1 METHODS FOR PREPARING IMMUNOGENIC CONJUGATES THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2005-12-15 WO disclosed
US-20050271675-A1 Methods for preparing immunogenic conjugates THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF 2005-12-08 US disclosed
WO-2005000884-A1 POLY-GAMMA-GLUTAMIC CONJUGATES FOR ELICITING IMMUNE RESPONSES DIRECTED AGAINST BACILLI THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2005-01-06 WO disclosed